FAGR Fagron SA

Fagron publishes agenda for annual shareholders meeting

Fagron publishes agenda for annual shareholders meeting

Regulated information

Nazareth (Belgium)/Rotterdam (The Netherlands), 7 April 2023 – 8AM CET

Fagron publishes agenda for annual shareholders meeting

The Board of Directors of Fagron NV invites shareholders and other persons authorized to attend general meetings to attend Fagron’s annual general meeting of shareholders on Monday 8 May 2023.

Agenda

The agenda includes the discussion of the annual report, the approval of the annual financial statements and the dividend proposal of €0.25 for the fiscal year 2022, and the approval of the remuneration policy. The remuneration policy provides for a long-term incentive plan for the members of Fagron’s executive leadership team, including the CEO and the CFO, based on the award of performance shares. Furthermore, the agenda includes several appointments:

  • The proposal to appoint Klaus Röhrig as non-executive director.
  • The proposal to reappoint AHOK BV, permanently represented by Mr. Koen Hoffman, as independent, non-executive director.
  • The proposal to approve the cooptation of and to appoint Els Vandecandelaere LLC, permanently represented by Els Vandecandelaere, as independent, non-executive director.

The full agenda and further details can be found in the meeting documents.

On the day of the shareholders’ meetings Management Deprez BV, represented by Veerle Deprez, will step down as independent, non-executive director.

Meeting and meeting documents

Fagron’s annual general meeting of shareholders will be held at its statutory seat, Venecoweg 20A, 9810, Nazareth (Belgium) and by audio and video conference on Monday 8 May 2023 at 3PM CET.

The convocation, including the agenda, and other documents related to the annual general meeting can be found on the Fagron .

Further information

Karen Berg

Global Investor Relations Manager

Tel. 99

About Fagron

Fagron is a leading global company active in pharmaceutical compounding, focusing on delivering personalized medicine to hospitals, pharmacies, clinics and patients in more than 30 countries around the world.

Belgian company Fagron NV has its registered office in Nazareth and is listed on Euronext Brussels and Euronext Amsterdam under the ticker symbol ‘FAGR’. Fagron’s operational activities are managed by the Dutch company Fagron BV, which is headquartered in Rotterdam.

In the event of differences between the English translation and the Dutch original of this press release, the latter prevails.

Please open the link below for the press release:



EN
07/04/2023

Underlying

To request access to management, click here to engage with our
partner Phoenix-IR's CorporateAccessNetwork.com

Reports on Fagron SA

Robert Jan Vos ... (+2)
  • Robert Jan Vos
  • Usama Tariq
ING Helpdesk
  • ING Helpdesk

Benelux Morning Notes

Company comments AB InBev: Little to disappoint Adyen: 2H25 results – mixed results, soft guidance CVC Capital Partners: Executing well dsm-firmenich: Messy results Fagron: Beat on all lines, confident FY26 outlook to drive c.5% consensus EBITDA upgrade Flow Traders: EMEA saves the day KBC: Good results, opening up “jaws” further to 2028 Kinepolis: Canadian peer Cineplex 4Q25 results below consensus, January 2026 box office revenue up MICC: FX headwind leads to a 50bp margin miss in FY25 Montea:...

Hilde Van Boxstael ... (+8)
  • Hilde Van Boxstael
  • Kristof Samoy
  • Lynn Hautekeete
  • Michiel Declercq
  • Thibault Leneeuw
  • Thomas Couvreur
  • Wim Hoste
  • Wim Lewi

Morning Notes : ABI BB, ADYEN NA, DSFIR NA, FAGR BB, FLOW NA, NEXTA BB...

: ABI BB, ADYEN NA, DSFIR NA, FAGR BB, FLOW NA, NEXTA BB, MONT BB, NN NA, ONTEX BB, SIP BB, WDP BB, NXFIL NA

ResearchPool Subscriptions

Get the most out of your insights

Get in touch